{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fidpodcast.simplecast.com%2Fepisodes%2Fnovel-hiv-art-ihm7VWhN","width":444,"version":"1.0","type":"rich","title":"Optimizing ART With Novel HIV Agents","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/19df6b27-52ea-4589-ae84-b74f012445d4/6298-contemporary-hiv-pod07-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/f277a612-4459-49d5-a786-8e048decff7b\" height=\"200\" width=\"100%\" title=\"Optimizing ART With Novel HIV Agents\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen as Gregory Huhn, MD, MPHTM, discusses a case study of a person with HIV and multiclass resistance, exploring when and how to consider agents with novel mechanisms of action."}